Health ❯ Healthcare ❯ Clinical Trials

Phase 2 Trials

Dostarlimab Weight Loss Studies WILLOW Trial NOBILITY Trial Clinical Study Results Silevertinib Trials Weight Loss Drugs Vaccine Efficacy AMT-130 KEYNOTE-942/mRNA-4157-P201

Cadonilimab Plus Chemo Delivers Strong Phase 2 Signal in Frontline Endometrial Cancer

The early signal suggests a possible first-line option for patients with pMMR tumors.

EMA Panel Backs Conditional EU Approval for Ojemda in Pediatric Low-Grade Glioma

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

Amgen Reports Year-Long Weight-Loss Maintenance With Monthly or Quarterly MariTide Dosing

Phase II Trial Finds 24 Gy Preoperative Radiation With Pembrolizumab Boosts T‑Cell Infiltration in HR+/HER2− Breast Cancer

Structure Therapeutics' Oral GLP-1 Posts Up to 15% Placebo-Adjusted Weight Loss as Company Prepares Phase 3

KOMET-007 Shows 600 mg Ziftomenib Plus Venetoclax/Azacitidine Achieves Deep Remissions in NPM1‑Mutated AML

FDA Approves Breyanzi for Marginal Zone Lymphoma After Two or More Therapies

Silevertinib Delivers 60% Response and Strong CNS Activity in First-Line NSCLC With Non-Classical EGFR Mutations

10-Minute UCL Scan Pinpoints Source of Aldosterone Excess in Hypertension

FDA Approves Epkinly Monotherapy and Triplet Regimen for Relapsed Follicular Lymphoma

FDA Approves Gazyva for Adults With Active Lupus Nephritis

Perioperative Immunotherapy and Liquid Biopsy Show Promise in Resectable Mesothelioma Phase 2 Trial

B7-H3 ADC Ifinatamab Deruxtecan Shows 48% Response in Relapsed ES-SCLC in Phase 2

FDA Approves Brensocatib as First Treatment for Non-Cystic Fibrosis Bronchiectasis

Amgen Advances Monthly Obesity Drug to Phase 3 After 20% Weight Loss in Mid-Stage Trial

Phase 3 Trial Launches to Test Electric Field and Immunotherapy Combo in Glioblastoma

Immunotherapy Shows 92% Success Rate in Avoiding Cancer Surgery

Novo Nordisk's Obesity Pill Shows Modest Results, Stocks Drop